SAVA — Cassava Sciences Income Statement
0.000.00%
- $207.72m
- $95.34m
- 26
- 18
- 60
- 26
Annual income statement for Cassava Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 6.45 | 32.9 | 80 | 106 | 141 |
| Operating Profit | -6.45 | -32.9 | -80 | -106 | -141 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -6.33 | -32.4 | -76.2 | -97.2 | -24.3 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -6.33 | -32.4 | -76.2 | -97.2 | -24.3 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -6.33 | -32.4 | -76.2 | -97.2 | -24.3 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -6.33 | -32.4 | -76.2 | -97.2 | -24.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.256 | -0.822 | -1.9 | -2.32 | -0.525 |